Non-alcoholic Fatty Liver Disease in Patients with Autoimmune Hepatitis

Overview

Journal JGH Open

Specialty Gastroenterology

Date 2018 Nov 29

PMID 30483564

Citations 22

Authors

Atsushi Takahashi

Teruko Arinaga-Hino

Hiromasa Ohira

Kazumichi Abe

Takuji Torimura

Mikio Zeniya

Masanori Abe

Kaname Yoshizawa

Akinobu Takaki

Yoshiyuki Suzuki

Jong-Hon Kang

Nobuhiro Nakamoto

Tomoo Fujisawa

Atsushi Tanaka

Hajime Takikawa

Affiliations

Soon will be listed here.

Abstract

Background And Aim: The incidence of non-alcoholic fatty liver disease (NAFLD) is increasing all over the world. NAFLD develops in patients with liver disease, including patients with autoimmune hepatitis (AIH). NAFLD and AIH have some similar laboratory and histological findings. The aim of this study was to elucidate the characteristics of AIH patients with NAFLD.

Methods: We re-evaluated the nationwide survey performed in Japan in 2015 of AIH patients diagnosed between 2009 and 2013.

Results: A total of 1151 subjects (144 men and 1007 women) were enrolled in the present study. The overall prevalence of NAFLD was 17.0%. Compared to AIH without NAFLD, AIH patients with NAFLD had the following characteristics: (i) low female-to-male ratio, (ii) older age, (iii) mild elevation in hepatobiliary enzymes, (iv) histologically progressive fibrosis and mild plasma cell infiltration or mild lobular hepatitis, (v) lower prevalence of prednisolone administration and higher prevalence of ursodeoxycholic acid administration, (vi) higher levels of hepatic enzymes and immunoglobulin G after treatment, and (vii) similar prevalence of autoimmune and malignant complications.

Conclusion: AIH patients with NAFLD have many features that are different from AIH patients without NAFLD. Understanding these differences is essential for the proper diagnosis and treatment of AIH patients with NAFLD.

Citing Articles

Hellenic Association for the Study of the Liver (HASL): revised clinical practice guidelines for autoimmune hepatitis.

Dalekos G, Papatheodoridis G, Koskinas J, Goulis I, Rigopoulou E, Tiniakos D Ann Gastroenterol. 2024; 37(6):623-654.

PMID: 39568707 PMC: 11574148. DOI: 10.20524/aog.2024.0924.

Liver fibrosis is closely linked with metabolic-associated diseases in patients with autoimmune hepatitis.

Liu K, Feng M, Chi W, Cao Z, Wang X, Ding Y Hepatol Int. 2024; 18(5):1528-1539.

PMID: 39249647 PMC: 11461548. DOI: 10.1007/s12072-024-10727-w.

Acute-on-chronic liver failure in metabolic dysfunction-associated fatty liver disease patients: a disease multiplier.

Choudhury A, Rajaram R, Sarin S Hepatol Int. 2024; 18(Suppl 2):941-958.

PMID: 39107615 DOI: 10.1007/s12072-024-10711-4.

PNPLA3 I148 M genetic variant in autoimmune hepatitis characterises advanced disease at diagnosis and reduced survival free of cirrhotic events and liver-related mortality.

Azariadis K, Gatselis N, Lyberopoulou A, Arvaniti P, Zachou K, Gabeta S J Transl Autoimmun. 2024; 9:100243.

PMID: 38974691 PMC: 11225017. DOI: 10.1016/j.jtauto.2024.100243.

Autoimmune Hepatitis with Metabolic Dysfunction-associated Fatty Liver Disease.

Takahashi A, Ohira H, Abe K, Zeniya M, Abe M, Arinaga-Hino T Intern Med. 2024; 64(3):337-342.

PMID: 38960681 PMC: 11867740. DOI: 10.2169/internalmedicine.3112-23.

References

Watanabe S, Hashimoto E, Ikejima K, Uto H, Ono M, Sumida Y . Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatol Res. 2015; 45(4):363-77. DOI: 10.1111/hepr.12511. View

Onji M, Zeniya M, Yamamoto K, Tsubouchi H . Autoimmune hepatitis: Diagnosis and treatment guide in Japan, 2013. Hepatol Res. 2015; 44(4):368-70. DOI: 10.1111/hepr.12300. View

Chalasani N, Younossi Z, Lavine J, Charlton M, Cusi K, Rinella M . The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2017; 67(1):328-357. DOI: 10.1002/hep.29367. View

Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G . A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010; 53(2):372-84. DOI: 10.1016/j.jhep.2010.04.008. View

Manns M, Czaja A, Gorham J, Krawitt E, Mieli-Vergani G, Vergani D . Diagnosis and management of autoimmune hepatitis. Hepatology. 2010; 51(6):2193-213. DOI: 10.1002/hep.23584. View

Loria P, Lonardo A, Leonardi F, Fontana C, Carulli L, Verrone A . Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates. Dig Dis Sci. 2004; 48(11):2173-81. DOI: 10.1023/b:ddas.0000004522.36120.08. View

De Luca-Johnson J, Wangensteen K, Hanson J, Krawitt E, Wilcox R . Natural History of Patients Presenting with Autoimmune Hepatitis and Coincident Nonalcoholic Fatty Liver Disease. Dig Dis Sci. 2016; 61(9):2710-20. PMC: 6357773. DOI: 10.1007/s10620-016-4213-3. View

Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K . The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005; 143(10):722-8. DOI: 10.7326/0003-4819-143-10-200511150-00009. View

Tsuneyama K, Baba H, Kikuchi K, Nishida T, Nomoto K, Hayashi S . Autoimmune features in metabolic liver disease: a single-center experience and review of the literature. Clin Rev Allergy Immunol. 2013; 45(1):143-8. DOI: 10.1007/s12016-013-8383-x. View

10.

Arinaga-Hino T, Ide T, Miyajima I, Ogata K, Kuwahara R, Amano K . Risk of malignancies in autoimmune hepatitis type 1 patients with a long-term follow-up in Japan. Hepatol Res. 2017; 48(3):E222-E231. DOI: 10.1111/hepr.12973. View

11.

. EASL Clinical Practice Guidelines: Autoimmune hepatitis. J Hepatol. 2015; 63(4):971-1004. DOI: 10.1016/j.jhep.2015.06.030. View

12.

Persico M, Iolascon A . Steatosis as a co-factor in chronic liver diseases. World J Gastroenterol. 2010; 16(10):1171-6. PMC: 2839168. DOI: 10.3748/wjg.v16.i10.1171. View

13.

Yatsuji S, Hashimoto E, Kaneda H, Taniai M, Tokushige K, Shiratori K . Diagnosing autoimmune hepatitis in nonalcoholic fatty liver disease: is the International Autoimmune Hepatitis Group scoring system useful?. J Gastroenterol. 2005; 40(12):1130-8. DOI: 10.1007/s00535-005-1711-z. View

14.

Adams L, Lindor K, Angulo P . The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic Fatty liver disease. Am J Gastroenterol. 2004; 99(7):1316-20. DOI: 10.1111/j.1572-0241.2004.30444.x. View

15.

Takahashi A, Arinaga-Hino T, Ohira H, Torimura T, Zeniya M, Abe M . Autoimmune hepatitis in Japan: trends in a nationwide survey. J Gastroenterol. 2016; 52(5):631-640. DOI: 10.1007/s00535-016-1267-0. View

16.

Loomba R, Sanyal A . The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013; 10(11):686-90. DOI: 10.1038/nrgastro.2013.171. View

17.

Eguchi Y, Hyogo H, Ono M, Mizuta T, Ono N, Fujimoto K . Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol. 2012; 47(5):586-95. DOI: 10.1007/s00535-012-0533-z. View

18.

Vernon G, Baranova A, Younossi Z . Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011; 34(3):274-85. DOI: 10.1111/j.1365-2036.2011.04724.x. View